Peter Marks, former head of the FDA's Center for Biologics Evaluation and Research (CBER), has joined Eli Lilly as senior vice president of molecule discovery and head of infectious disease. Marks led the FDA's vaccine and gene therapy reviews for nearly a decade and was instrumental in the Operation Warp Speed COVID-19 vaccine approvals. His appointment marks a strategic strengthening of Eli Lilly's pipeline and expertise, despite his prior conflict with Health and Human Services Secretary Robert F. Kennedy Jr. that led to his FDA resignation earlier in 2025.